Zacks: Analysts Anticipate Minerva Neurosciences Inc (NASDAQ:NERV) Will Announce Earnings of -$0.42 Per Share

Equities research analysts predict that Minerva Neurosciences Inc (NASDAQ:NERV) will post earnings of ($0.42) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences reported earnings of ($0.32) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 31.3%. The business is scheduled to issue its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Minerva Neurosciences will report full-year earnings of ($1.71) per share for the current financial year, with EPS estimates ranging from ($1.79) to ($1.62). For the next year, analysts forecast that the firm will post earnings of ($2.66) per share, with EPS estimates ranging from ($3.31) to ($2.01). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06).

A number of equities research analysts recently weighed in on NERV shares. HC Wainwright started coverage on Minerva Neurosciences in a research report on Friday, May 31st. They set a “buy” rating and a $22.00 price objective on the stock. ValuEngine upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. BidaskClub upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Finally, Zacks Investment Research lowered Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th.

Shares of NERV stock opened at $4.70 on Friday. The firm has a market cap of $192.81 million, a P/E ratio of -3.64 and a beta of 1.62. Minerva Neurosciences has a twelve month low of $4.65 and a twelve month high of $12.95.

In other Minerva Neurosciences news, major shareholder Venture Associates L. Index III sold 134,828 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $6.66, for a total value of $897,954.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Venture Associates L. Index III sold 36,574 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $7.05, for a total value of $257,846.70. The disclosure for this sale can be found here. Insiders sold a total of 171,602 shares of company stock worth $1,157,017 in the last quarter. Corporate insiders own 12.00% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its position in shares of Minerva Neurosciences by 16.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,318 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 1,782 shares during the last quarter. Citigroup Inc. grew its position in shares of Minerva Neurosciences by 23.1% in the 1st quarter. Citigroup Inc. now owns 9,753 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,829 shares during the last quarter. Swiss National Bank grew its position in shares of Minerva Neurosciences by 4.9% in the 1st quarter. Swiss National Bank now owns 60,203 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 2,800 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Minerva Neurosciences by 4.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,448 shares of the biopharmaceutical company’s stock valued at $539,000 after buying an additional 2,881 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Minerva Neurosciences by 17.0% in the 4th quarter. Bank of America Corp DE now owns 20,412 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 2,963 shares during the last quarter. Hedge funds and other institutional investors own 77.00% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Further Reading: What economic reports are most valuable to investors?

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.